ERBB2 and breast carcinoma: More recently, when compared with placebo, E75 vaccination failed to improve the disease-free survival of patients with HER2-expressing, high-risk breast cancer in a randomized phase 3 trial, leading to the conclusion that synergistic combinations may be needed93.